Transcenta Holding Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Xueming Qian

Chief executive officer

CN¥5.6m

Total compensation

CEO salary percentage	20.3%
CEO tenure	11.8yrs
CEO ownership	7.0%
Management average tenure	2.5yrs
Board average tenure	2.8yrs

Recent management updates

Recent updates

Calculating The Intrinsic Value Of Transcenta Holding Limited (HKG:6628)

Dec 15

CEO Compensation Analysis

How has Xueming Qian's remuneration changed compared to Transcenta Holding's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	CN¥6m	CN¥1m	-CN¥463m
Sep 30 2023	n/a	n/a	-CN¥451m
Jun 30 2023	n/a	n/a	-CN¥440m
Mar 31 2023	n/a	n/a	-CN¥424m
Dec 31 2022	CN¥6m	CN¥1m	-CN¥407m
Sep 30 2022	n/a	n/a	-CN¥666m
Jun 30 2022	n/a	n/a	-CN¥925m
Mar 31 2022	n/a	n/a	-CN¥2b
Dec 31 2021	CN¥5m	CN¥1m	-CN¥2b
Sep 30 2021	n/a	n/a	-CN¥1b
Jun 30 2021	n/a	n/a	-CN¥1b
Mar 31 2021	n/a	n/a	-CN¥364m
Dec 31 2020	CN¥51m	CN¥1m	-CN¥317m
Dec 31 2019	CN¥14m	CN¥823k	-CN¥395m

Compensation vs Market: Xueming's total compensation ($USD765.23K) is above average for companies of similar size in the Hong Kong market ($USD233.46K).

Compensation vs Earnings: Xueming's compensation has been consistent with company performance over the past year.

CEO

Xueming Qian (55 yo)

11.8yrs

Tenure

CN¥5,562,000

Compensation

Dr. Xueming Qian, Ph.D. has been Chief Executive Officer and Executive Director at Transcenta Holding Limited and serves as its Chairman since June 07, 2024. He was the Founder, Chairman and Chief Executiv...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Xueming Qian	CEO & Executive Chairman	no data	CN¥5.56m	6.99% CN¥ 42.7m
Xiaolu Weng	Executive VP & CFO	2.6yrs	CN¥8.32m	no data
Feng Ye	Executive VP & COO	4.4yrs	no data	no data
Christopher Hwang	Executive VP & CTO	5.4yrs	no data	no data
Wei Wang	VP of Investor Relations & Capital Markets Department and Secretary to the Board	2.3yrs	no data	no data
Yi Gu	Senior VP & Head of Research	5.4yrs	no data	no data
Charlie Qi	Senior Vice President of Global Clinical Development	1.4yrs	no data	no data
Xichen Zhang	Senior Vice President of Manufacturing	2.5yrs	no data	no data
Wen-I Chang	Senior Vice President of Oncology Franchise Strategy	2.3yrs	no data	no data
Caroline Germa	Executive VP of Global Medicine Development & Chief Medical Officer	1.9yrs	no data	no data
Kwan Wai Leung	Company Secretary	3.1yrs	no data	no data

2.5yrs

Average Tenure

53.5yo

Average Age

Experienced Management: 6628's management team is considered experienced (2.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Xueming Qian	CEO & Executive Chairman	11.8yrs	CN¥5.56m	6.99% CN¥ 42.7m
Briggs W. Morrison	Chairman of Scientific Advisory Board	no data	no data	no data
Pasi Antero Janne	Member of Scientific Advisory Board	no data	no data	no data
Kumar Srinivasan	Independent Non-Executive Director	1.6yrs	CN¥226.00k	no data
Ling Su	Member of Scientific Advisory Board	no data	no data	no data
Wei Chen	Independent Non-Executive Director	less than a year	CN¥72.00k	no data
Susan M. Jerian	Member of Scientific Advisory Board	no data	no data	no data
Li Xu	Member of Scientific Advisory Board & Strategic Advisor to CEO	3.4yrs	no data	no data
Jiasong Tang	Independent Non-Executive Director	2.8yrs	CN¥219.00k	no data
Zhihua Zhang	Independent Non-Executive Director	2.8yrs	CN¥219.00k	no data

2.8yrs

Average Tenure

56yo

Average Age

Experienced Board: 6628's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Transcenta Holding Management

Management criteria checks 2/4

Key information

Recent management updates

Transcenta Holding Limited Announces Directorate and Board Changes

Transcenta Holding Limited Announces Board and Nomination Changes

Transcenta Holding Limited, Annual General Meeting, Jun 07, 2024

CEO & Executive Director recently bought HK$74k worth of stock

Transcenta Holding Limited Announces Management Changes, Effective August 23, 2023

CEO & Executive Director recently bought HK$50k worth of stock

Recent updates

Transcenta Holding Limited Announces Directorate and Board Changes

Consensus EPS estimates fall by 36%

Transcenta Holding Limited Announces Updates of Phase II Data from First-Line Triple Combination Trial of Osemitamab (TST001) for G/GEJ Cancer at ASCO 2024

Transcenta Holding Limited Announces Board and Nomination Changes

New minor risk - Market cap size

Consensus revenue estimates decrease by 17%, EPS upgraded

Transcenta Holding Limited, Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: CN¥1.14 loss per share (vs CN¥0.94 loss in FY 2022)

Transcenta Holding Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Calculating The Intrinsic Value Of Transcenta Holding Limited (HKG:6628)

CEO & Executive Director recently bought HK$74k worth of stock

Transcenta Holding Limited Announces the Publication of Preclinical Results of [177Lu]Lu-TST001 Radionuclide Antibody Conjugate as Potential Novel Treatment Option for Metastatic Gastric Cancer in the European Journal of Nuclear Medicine and Molecular Imaging

FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab (TST001) as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients

New minor risk - Shareholder dilution

First half 2023 earnings released: CN¥0.58 loss per share (vs CN¥0.47 loss in 1H 2022)

Transcenta Holding Limited Announces Management Changes, Effective August 23, 2023

Transcenta Holding Limited to Report First Half, 2023 Results on Aug 22, 2023

Transcenta Holding Limited Receives Approval from China Center for Drug Evaluation to Initiate Phase II Clinical Trial of TST002(Blosozumab)

CEO & Executive Director recently bought HK$50k worth of stock

Transcenta Holding Limited Receives Approval from China CDE and South Korea MFDS to Initiate Transtar301 Global Phase III Pivotal Trial of Osemitamab (TST001)

CEO & Executive Director recently bought HK$70k worth of stock

Transcenta Holding Limited Announces Update on Efficacy Data of Osemitamab Plus Capecitabine and Oxaliplatin

CEO & Executive Director recently bought HK$54k worth of stock

Transcenta Holding Limited Presents Updated Data of Cohort C from Phase I/IIa, Multi-Center Study of Osemitamab

CEO & Executive Director recently bought HK$70k worth of stock

Transcenta Holding Limited Announces Encouraging Phase I Clinical Data of TST002 (Blosozumab) in Chinese Patients with Reduced Bone Mineral Density

Transcenta Holding Limited to Present Two Clinical Trial Progress At Asco 2023

Transcenta Holding Limited Announces Completion of Enrollment in COHorts C and G of China Phase II Study of Osemitamab (TST001) in Combination with Capecitabine and Oxaliplatin

CEO & Executive Director recently bought HK$72k worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Transcenta Holding Limited to Present "Trial in Progress" at ASCO-GI 2023 for TST001 (Osemitamab) Combination with Nivolumab, with or without Chemotherapy in Advanced G/GEJ Cancer

Transcenta Receives IND Clearance from NMPA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors

Transcenta Holding Limited Announces Appointment of Independent Non-Executive Director and Change in the Composition of Board Committees

High number of new and inexperienced directors

CEO & Executive Director recently bought HK$78k worth of stock

Transcenta Holding Limited Provides Update on Prevalence of Claudin18.2 and PD-L1 Expression in Chinese Gastric/Gastroesophageal Junction Adenocarcinoma

Transcenta Holding Limited Receives IND Clearance from FDA for its MASP2 Targeting Antibody TST004 for Treatment of IgA Nephropathy

CEO & Executive Director recently bought HK$72k worth of stock

Transcenta Holding Limited Receives IND Clearance from FDA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors

Transcenta Holding Limited Announces that Interim Safety and Efficacy Data of Dose Expansion Cohort from the Phase I/II Study of TST001 (Osemitamab)

Transcenta Releases Encouraging Interim Safety and Efficacy Data of the TST001 (Osemitamab) and Chemotherapy Combination Expansion Cohort for First Line Claudin18.2 Positive Gastric Cancer at ESMO Congress 2022

First half 2022 earnings released: CN¥0.47 loss per share (vs CN¥10.19 loss in 1H 2021)

Transcenta Holding Limited to Report First Half, 2022 Results on Aug 29, 2022

Transcenta Holding Limited Announces the Appointment of Caroline Germa as Executive Vice President, Global Medicine Development and Chief Medical Officer

Transcenta Holding Limited Announces Change of the Chief Medical Officer

Transcenta Holding Limited Announces Resignation of Michael Ming Shi as Executive Director

Transcenta Holding Limited Announces That It Was Selected to Present the Preclinical Data of Tst004 At the 2022 Isn Frontiers Meetings of Complement-Related Kidney Diseases

Transcenta Holding Limited Announces Demise of Albert Da Zhu, an Executive Director and a Joint Company Secretary

Transcenta Holding Limited Publishes the Results of Preclinical Studies of the Company's First-In-Class Gremlin1 Targeting Antibody in the Treatment of Castration Resistant Prostate Cancer

Less than half of directors are independent

Transcenta Holding Limited Successfully Passes the Audit of EU Qualified Person for the Manufacturing of TST001

CEO & Executive Director recently bought HK$59k worth of stock

Transcenta Holding Limited, Annual General Meeting, Jun 10, 2022

Transcenta Announces First Patient Dosed in Phase IIa Study of Claudin18.2 Monoclonal Antibody TST001 Combined with Cisplatin and Gemcitabine for the First Line Treatment of Biliary Tract Cancer

Transcenta Holding Limited to Present Two Phase I Clinical Trials of Tst001 at Upcoming ASCO GI and IGCC

CEO & Executive Director recently bought HK$864k worth of stock

Transcenta Holding Limited Announces Business Update on the First Patient Dosed in Thephase Ib Clinical Trial of Humanized Anti-Vegfr-2Monoclonal Antibody Msb0254

Transcenta Holding Limited has completed an IPO in the amount of HKD 645.28 million.

Less than half of directors are independent

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age